The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.

Pınar Özcan Cenksoy

Status and phase: Unknown; Phase 4

Conditions: Poor Responders Undergoing IVF

Treatments: Drug: microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono); Drug: Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma); Drug: GnRH antagonist protocol (Cetrotide, Serono); Drug: GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)

Study type: Interventional

Funder types: Other

Identifiers

NCT01948804

ytu-123 (Other Identifier)

Details and patient eligibility

About

The comparison of effect of four different treatment protocols: Antagonist/letrozole protocol, microdose flare-up protocol, Antagonist/clomiphene protocol, Antagonist on IVF outcomes in poor responders undergoing in vitro fertilization; a prospective randomized-controlled study.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 44 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Criteria for definition of poor responders included at least one of the following

1. Anti müllerian hormone <1.1 ng/ml and/or a previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol).
2. Primary infertile patients
3. BMI≤30 kg/m2 were included this study.

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 1 patient group

IVF patients

Experimental group

Description:

patients that has applied to Yeditepe University Hospital assisted reproduction center

Treatment:

Drug: Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)

Drug: microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)

Drug: GnRH antagonist protocol (Cetrotide, Serono)

Drug: GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)